Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Orally active fibrinogen antagonist developed by Merck

May 3, 1999

Potent and selective small-molecule thrombin inhibitor developed at DuPont

April 30, 1999

Definitive copromotion agreement for cilostazol signed by Otsuka and Pharmacia & Upjohn

April 29, 1999

Aggrenox unanimously recommended for approval for stroke indication

April 29, 1999

Merck & Co. discovers new series with antithrombin effects

April 23, 1999

SmithKline Beecham synthesizes pharmaceutically active integrin receptor antagonists

April 23, 1999

Merck identifies a nonpeptide, linearly minimized, centrally constrained gpIIb/IIIa antagonist

April 22, 1999

News from FASEB: novel factor Xa inhibitor presented by DuPont Pharmaceuticals

April 22, 1999

European Commission approves novel albumin-free treatment for hemophilia A

April 19, 1999

NovoSeven reaches the U.S. hemophilia market

April 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 26, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026